Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

The Prostate - 1 Nov 2007

Neslund-Dudas Christine, Bock Cathryn H, Monaghan Kristin, Nock Nora L, Yang James J, Rundle Andrew, Tang Deliang, Rybicki Benjamin A

Abstract excerpt

BACKGROUND: Dihydrotestosterone (DHT) is believed to play an important role in prostate carcinogenesis. Five alpha reductase type II (SRD5A2) and 3 beta-hydroxysteroid dehydrogenase type II (HSD3B2) are responsible for the biosynthesis and degradation of DHT in the prostate. Two polymorphisms, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Hydroxysteroid Dehydrogenases
Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Black or African American

Share to Michigan

Share to Population Surveillance

Share to Prostatic Neoplasms

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 17823934
DOI: 10.1002/pros.20625
PMCID: PMC2132439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17823934-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.PMID 17823934Read ↗

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.Semantic proximity Read ↗

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).Semantic proximity Read ↗

Polymorphism of the SRD5A2 gene and the risk of prostate cancer.Semantic proximity Read ↗

Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.Semantic proximity Read ↗

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.Semantic proximity Read ↗

Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.Semantic proximity Read ↗

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.